* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a rise in quarterly revenue when it reports
results on February 28 for the period ending December 31 2023
* The Princeton New Jersey-based company is expected to
report a
0.3% increase in revenue to $399.338 million from $398.02
million a year ago, according to the mean estimate from 11
analysts, based on LSEG data.The company's guidance on October
25 2023, for the period ended December 31, was for revenue
between $397.00 million and $403.00 million.
* LSEG's mean analyst estimate for Integra Lifesciences
Holdings
Corp is for earnings of 90 cents per share. The company's EPS
guidance on October 25 2023, for the period ended December
31, was between $0.89 and $0.93
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 5
"hold" and 4 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $47.50, above its last closing
price of $44.73.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 0.78 0.78 0.76 Missed -2.3
Jun. 30 2023 0.57 0.57 0.71 Beat 24.8
Mar. 31 2023 0.74 0.74 0.74 Met 0.4
Dec. 31 2022 0.91 0.90 0.94 Beat 4.1
Sep. 0.71 0.72 0.86 Beat 19.5
30 2022
Jun. 30 2022 0.80 0.80 0.81 Beat 1.6
Mar. 31 2022 0.68 0.68 0.74 Beat 8.8
Dec. 31 2021 0.84 0.83 0.84 Beat 0.7
This summary was machine generated February 26 at 14:29 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)